Châtillon, France, June 5, 2024
DBV Technologies to Participate in the Goldman Sachs 45(th) Annual Global Healthcare Conference
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the 45(th) Annual Goldman Sachs Global Healthcare Conference on Monday, June 10(th), at 8:00 am EDT, as well as in one-
on-one investor meetings.
A live webcast of the presentation can be accessed here
(https://url.avanan.click/v2/___https:/cc.webcasts.com/gold006/061024a_js/?entit
y=133_TOP60LN___.YXAzOmRidi10ZWNobm9sb2dpZXM6YTpvOmVjYTRlYmMzN2ZjNzMzZGFhZTY5MjF
lYTk4NjA4Yzg3OjY6OTkxNzowMDExMWY1MTgzZmRkNDc0YmMzMmJjMGY2MjFkNzk1ZGFlMWUwODQxZjk
wZmRjZDg5NzI0ZGEyNmEzODFiODM3OnA6VA), and will also be available on the Events
section of Company's Investors website: https://dbv-technologies.com/investor-
overview/events/
A replay will also be available on DBV Technologies' website for 90 days after the event.
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing
treatment options for food allergies and other immunologic conditions with
significant unmet medical need. DBV is currently focused on investigating the
use of its proprietary technology platform, Viaskin(TM), to address food allergies,
which are caused by a hypersensitive immune reaction and characterized by a
range of symptoms varying in severity from mild to life-threatening anaphylaxis.
Millions of people live with food allergies, including young children. Through
epicutaneous immunotherapy (EPIT(TM)), the Viaskin platform is designed to
introduce microgram amounts of a biologically active compound to the immune
system through intact skin. EPIT is a new class of non-invasive treatment that
seeks to modify an individual's underlying allergy by re-educating the immune
system to become desensitized to allergen by leveraging the skin's immune
tolerizing properties. DBV is committed to transforming the care of food
allergic people. The Company's food allergy programs include ongoing clinical
trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age)
and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company's ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Stock Market (Ticker: DBVT).
For more information, please visit www.dbv-technologies.com (http://www.dbv- technologies.com/) and engage with us on X (formerly Twitter) (https://twitter.com/DBVTechnologies) and LinkedIn (https://www.linkedin.com/company/dbv-technologies/).
Viaskin and EPIT are trademarks of DBV Technologies.
Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com (mailto:katie.matthews@dbv-technologies.com)
Media Contact
Angela Marcucci
DBV Technologies
angela.marcucci@dbv-technologies.com (mailto:angela.marcucci@dbv- technologies.com)
Â